SeaStar Medical (NASDAQ:ICU) Issues Earnings Results, Misses Expectations By $0.08 EPS

SeaStar Medical (NASDAQ:ICU) released its quarterly earnings results on Wednesday. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.08), Zacks reports. SeaStar Medical had a negative net margin of 795.51% and a negative return on equity of 162.75%.

SeaStar Medical Stock Up 1.1%

Shares of SeaStar Medical stock traded up $0.02 on Wednesday, hitting $1.92. 142,183 shares of the company’s stock traded hands, compared to its average volume of 130,616. The stock has a market cap of $10.21 million, a P/E ratio of -0.49 and a beta of -1.07. The firm’s 50-day moving average is $3.03 and its 200 day moving average is $3.29. SeaStar Medical has a 52-week low of $1.84 and a 52-week high of $5.38.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a report on Thursday, October 15th. Wall Street Zen upgraded SeaStar Medical from a “sell” rating to a “hold” rating in a research note on Saturday, September 19th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, SeaStar Medical presently has an average rating of “Hold” and a consensus target price of $8.00.

About SeaStar Medical

SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company developing therapies designed to address hyperinflammation, an excessive immune response that can contribute to organ damage in critically ill patients. The company’s platform is intended to selectively target and modulate pro-inflammatory immune cells while preserving the body’s broader immune function. Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-purification device used alongside continuous kidney replacement therapy.